neuro-oncology
(2)
Orbus Bet $71 Million on One Brain-Cancer Trial - Then the Definition of the Disease Changed
A tiny Palo Alto biotech took an old molecule into a global Phase 3 trial. The broad result failed, but a new molecular map of brain cancer revealed where the drug may actually work - and offered a playbook for anyone building in a market whose definitions move mid-experiment.
GT Medical Technologies, Inc.
GT Medical Technologies is a Tempe, Arizona medical device company that developed GammaTile, an FDA-cleared bioresorbable radiation therapy implant for operable brain tumors. Founded by brain tumor specialists from the Barrow Neurological Institute, the company places collagen tiles embedded with Cesium-131 seeds directly into the tumor cavity at the time of surgery, delivering immediate, targeted radiation while sparing healthy tissue. Backed by a $100M Series E led by Viking Global Investors, GT Medical has treated more than 2,000 patients and is pursuing randomized trials to establish GammaTile as a standard of care.